Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Ilaria Pergolini

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3511-5882; OpenAlex author ID A5001227487. Sources: OpenAlex.

Their work

Papers
16 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
72
Papers, trials and grants by year

2017: 2 papers · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 3 papers · 2025: 1 paper · 2026: 2 papers

Papers 16

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  2. Heterogeneity in the management of patients with locally advanced pancreatic cancer: current surgeons' perspective and lessons for the future. Co-author DOI 10.1007/s13304-026-02651-5↗
  3. Pancreatic cancer cells survive in the neural niche during neoadjuvant therapy. Co-author DOI 10.1016/j.canlet.2025.217894↗
  4. A retrospective, multicentric, nationwide analysis of the impact of splenectomy on survival of pancreatic cancer patients. Co-author DOI 10.1007/s00423-024-03570-y↗
  5. Correlation of intratumoral mast cell quantity with psychosocial distress in patients with pancreatic cancer: the PancStress study. Co-author DOI 10.1038/s41598-024-77010-8↗
  6. Lymph node examination and survival in resected pancreatic ductal adenocarcinoma: retrospective study. Co-author DOI 10.1093/bjsopen/zrad125↗
  7. Arterial Resection for Pancreatic Cancer: Feasibility and Current Standing in a High-Volume Center. Co-author DOI 10.1097/as9.0000000000000302↗
  8. The Effect of Celiac Neurolysis and Splanchnicectomy on Survival in Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.1159/000520456↗
  9. Effects of COVID-19 Pandemic on the Treatment of Pancreatic Cancer: A Perspective from Central Europe. Co-author DOI 10.1159/000513157↗
  10. Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer. First author DOI 10.1097/sla.0000000000003123↗
  11. Prognostic impact of Ki-67 proliferative index in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/bjs5.50175↗
  12. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. First author DOI 10.1097/sla.0000000000002600↗
  13. SUVmax after (18)fluoro-deoxyglucose positron emission tomography/computed tomography: A tool to define treatment strategies in pancreatic cancer. Co-author DOI 10.1016/j.dld.2017.09.122↗
  14. Systematic review and meta-analysis of prognostic role of splenic vessels infiltration in resectable pancreatic cancer. Co-author DOI 10.1016/j.ejso.2017.10.217↗
  15. Reappraisal of Staging Laparoscopy for Patients with Pancreatic Adenocarcinoma: A Contemporary Analysis of 1001 Patients. Co-author DOI 10.1245/s10434-017-5973-5↗
  16. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. Co-author DOI 10.1371/journal.pone.0182855↗

Closest collaborators

The 25 strongest of 72 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. İhsan Ekin Demir · 8 shared papers, 2021–2026 · strength 1.51
  2. Helmut Friess · 7 shared papers, 2022–2026 · strength 1.36
  3. Guralp Onur Ceyhan · 7 shared papers, 2022–2026 · strength 1.36
  4. Alexander Novotny · 5 shared papers, 2021–2026 · strength 0.95
  5. Rüdiger Göß · 5 shared papers, 2023–2025 · strength 0.89
  6. Okan Safak · 5 shared papers, 2022–2024 · strength 0.81
  7. Stephan Schorn · 4 shared papers, 2022–2024 · strength 0.65
  8. Marc Eric Martignoni · 3 shared papers, 2023–2026 · strength 0.62
  9. Carmen Mota Reyes · 3 shared papers, 2024–2025 · strength 0.54
  10. Mert Erkan · 2 shared papers, 2024–2026 · strength 0.48
  11. Alexander Muckenhuber · 2 shared papers, 2024–2025 · strength 0.42
  12. Ugo Boggi · 1 shared paper, 2026 · strength 0.32
  13. Maximilian Kießler · 2 shared papers, 2023–2024 · strength 0.30
  14. Carlos F. Fernandez-del Castillo · 4 shared papers, 2017–2020 · strength 0.30
  15. Andrew Louis Warshaw · 4 shared papers, 2017–2020 · strength 0.30
  16. Keith D. Lillemoe · 4 shared papers, 2017–2020 · strength 0.30
  17. Stefano Partelli · 3 shared papers, 2018–2019 · strength 0.26
  18. Massimo Falconi · 3 shared papers, 2018–2019 · strength 0.26
  19. Stefano Crippa · 3 shared papers, 2018–2019 · strength 0.26
  20. Kaan Çifcibaşı · 1 shared paper, 2025 · strength 0.24
  21. Tobias Keck · 2 shared papers, 2020–2024 · strength 0.23
  22. Kim C. Honselmann · 3 shared papers, 2017–2020 · strength 0.23
  23. Mustapha Adham · 1 shared paper, 2024 · strength 0.18
  24. Florian Scheufele · 1 shared paper, 2024 · strength 0.18
  25. Julie Périnel · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.